It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue 139 (known as γH2AX), resulting in the recruitment of the DNA repair effectors 53BP1 and BRCA1. Here, by studying resistance to poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2-deficient mammary tumours, we identify a function for γH2AX in orchestrating drug-induced replication fork degradation. Mechanistically, γH2AX-driven replication fork degradation is elicited by suppressing CtIP-mediated fork protection. As a result, H2AX loss restores replication fork stability and increases chemoresistance in BRCA1/2-deficient tumour cells without restoring homology-directed DNA repair, as highlighted by the lack of DNA damage-induced RAD51 foci. Furthermore, in the attempt to discover acquired genetic vulnerabilities, we find that ATM but not ATR inhibition overcomes PARP inhibitor (PARPi) resistance in H2AX-deficient tumours by interfering with CtIP-mediated fork protection. In summary, our results demonstrate a role for H2AX in replication fork biology in BRCA-deficient tumours and establish a function of H2AX separable from its classical role in DNA damage signalling and DSB repair.
Histone H2AX has a known role in DNA damage repair but interestingly, its loss is associated with resistance to poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-deficient tumours. Here, the authors identify a role of γH2AX in the degradation of replication forks and demonstrate that H2AX loss drives PARP inhibitor resistance via increased stressed fork stability in BRCA-deficient tumours.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Department of Experimental Oncology, Milan, Italy (GRID:grid.4527.4) (ISNI:0000 0001 0667 8902)
2 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
3 University of Zürich, Institute of Molecular Cancer Research, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
4 The Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Amsterdam, The Netherlands (GRID:grid.499559.d)
5 AstraZeneca, DDR Biology, Bioscience, Oncology R&D, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
6 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
7 Oncode Institute, Amsterdam, The Netherlands (GRID:grid.499559.d); University of Copenhagen, Biotech Research and Innovation Centre, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
8 University of Copenhagen, Biotech Research and Innovation Centre, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
9 Hôpitaux Universitaires de Genève, Division of Clinical Pathology, Department of Diagnostics, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812)
10 Hôpitaux Universitaires de Genève, Division of Gynecology, Department of Pediatrics and Gynecology, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812)
11 Swiss Cancer Center Leman, Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Geneva, Switzerland (GRID:grid.511014.0); Rue Gabrielle Perret-Gentil, Department of Oncology, Hôpitaux Universitaires de Genève, 4, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812)
12 University of Bern, Institute of Animal Pathology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); The Netherlands Cancer Institute, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)